

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicants: Borodic et al.

Serial No.: TBA

Filed: January 7, 2002

For: THE USE OF BOTULINUM TOXIN FOR THE TREATMENT OF
CHRONIC FACIAL PAINGroup Art Unit: TBAAssistant Commissioner for Patents
Washington, D.C. 20231**Information Disclosure Statement**

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicant hereby makes the following documents
of record in this application:

Document Title/ Source	Document Title/ Source/Date/Page #'s
Acquadro, M. et al.	Treatment of myofascial pain with botulinum A toxin. <i>Anesthesiology</i> , 3/94; 80(3): 705-6.
Anderson, R. et al.	Blepharospasm past, present and future. <i>Ophthal Plast Reconstr Surgery</i> , 1998; 14(5): 305-17.
Barker, F. et al.	The long term outcome of microvascular decompression for trigeminal neuralgia. <i>N Engl J Med</i> , 1996; 334: 1077-83.
Boghen, D. et al.	Effectiveness of botulinum toxin in the treatment of spasmodic torticollis. <i>Eur Neurol</i> , 1993; 33(3): 199-203.
Borodic, G.	Myasthenic crisis after botulinum toxin. <i>Lancet</i> , 12/5/98; 352(9143): 1832.
Borodic, G. et al.	Blepharospasm and its treatment, with emphasis on the use of botulinum A toxin. <i>Plast Reconstr Surg</i> , 3/89; 83(3): 546-54.
Borodic, G. et al.	Botulinum A toxin for the treatment of adult-onset spasmodic torticollis. <i>Plast Reconstr Surg</i> , 2/91; 87(2): 285-9.
Borodic, G. et al.	Botulinum toxin therapy, immunologic resistance, and problems with available materials. <i>Neurology</i> , 1/96; 46(1): 26-29.
Buzzi, M. et al.	5-Hydroxytryptamine receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial and platelet activation within the rat dura mater after trigeminal stimulation. <i>Brain Res</i> , 6/26/92; 528(1-2): 127.
Buzzi, M. et al.	Neurogenic model for migraine. <i>Cephalgia</i> , 1995; 15(4): 277-289.



Costigan, M. et al.	Pain: molecular mechanisms. <i>The Journal of Pain, Supplement 1, 2000; 1: 35-44.</i>
Fields, H.	Treatment of trigeminal neuralgia. <i>N Engl J Med, 4/25/96; 334(17): 1125-6.</i>
Johnson, E.	Clostridial toxins as therapeutic agents: benefits of nature's most toxin proteins. <i>Annu Rev Microbiol, 1999; 53: 551-75.</i>
Mauriello, J. et al.	Long term enhancement of botulinum toxin injections by upper eyelid surgery in 14 patients with facial dyskinesia. <i>Arch Otolaryngol Head Neck Surg, 1999; 125(6): 627-31.</i>
Poewe, W. et al.	Use of botulinum toxin in the treatment of cervical dystonia. <i>Baillieres Clin Neurol, 4/93; 2(1): 179-85.</i>
Sessle, B.	Neural mechanisms of oral and facial pain. <i>Otolaryngologic Clinics of North America, 1989; 22(6): 1059-72.</i>
Siberstein, S. et al.	Botulinum toxin type A as a migraine preventive treatment. <i>Headache, 6/00; 40(6): 445-50.</i>
Wilkinson, H.	Trigeminal nerve peripheral branch phenol/glycerol injections for tic douloureux. <i>J Neurosurg, 1999; 90(5): 828-32.</i>
Woolf, C. et al.	Neuropathic pain: aetiology, symptoms, mechanisms, and management. <i>Lancet, 1999; 353: 1959-64.</i>
Woolf, C. et al.	Transcriptional and posttranslational plasticity and the generation of inflammatory pain. <i>Proc. Natl. Acad. Sci. 1999; 96: 7723-30.</i>
Yoon, K. et al.	Long term outcome of percutaneous thermocoagulation for trigeminal neuralgia. <i>Anesthesia, 08/99; 54(8): 803-808.</i>

The aforementioned documents are listed on the accompanying Form PTO-1449 (submitted herewith in duplicate) and copies thereof are enclosed herewith.

It is respectfully requested that the aforementioned documents be (1) fully considered by the Patent and Trademark Office, and (2) printed on any patent which may issue on this application. Applicants request that a copy of Form PTO-1449, as considered and initialed by the Examiner, be returned with the next communication.

Date: January 8, 2002

Respectfully submitted,



Michael N. Nitabach, Ph.D.
Reg. No. 47,344
Milbank, Tweed, Hadley & McCloy LLP
1 Chase Manhattan Plaza
New York, New York 10005

NY2:#4441452